Oncopeptides Q1 2025: Sequential sales growth of 34% - Redeye

Redeye provides its first take on Oncopeptides' Q1 report 2025, published this morning. Sales grew 34% versus Q4 2024, a respectable number. Operating costs amounted to SEK-73m, an improvement from Q4, with an EBIT of SEK-61m. Overall, the quarter was in line with our expectations.

Länk till analysen i sin helhet: https://www.redeye.se/research/1109127/oncopeptides-q1-2025-sequential-sales-growth-of-34?utm_source=finwire&utm_medium=RSS